Using MRI scans to personalize radiotherapy for high grade glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of repeated magnetic resonance imaging (MRI) scans in monitoring tumor changes during radiation and chemotherapy for patients with high grade glioma. It aims to compare the dosimetric coverage of the tumor using immediate post-operative MRI versus newly acquired MRI before radiation therapy. Additionally, the study evaluates the relationship between MRI findings and tumor progression, neurocognitive function, and overall survival. By adapting treatment plans based on serial MRI data, the study seeks to improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with histologic confirmation of high grade glioma
* Patients must be age \>= 18 years
* Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol, and has been approved and amended by the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB)
* Patients must have Karnofsky performance status (KPS) \>= 60
* Patients must be able to obtain an MRI scan with gadolinium contrast
* Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breastfeeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Female patients who consent to participate in the study will need to use contraceptive methods for the duration of the study

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Caroline Chung — M.D. Anderson Cancer Center
• Study coordinator: Caroline Chung
• Email: cchung3@mdanderson.org
• Phone: 713-563-2300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• T2* MRI and blood tests to predict progression of malignant gliomas

  This trial tests whether T2* MRI scans and blood biomarkers can help predict how WHO grade IV malignant gliomas will change or come back in adults.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07447531

• Mapping electrical properties in the brain

  This study is testing new MRI methods to see if they can help doctors better understand and diagnose brain tumors by looking at the brain's electrical activity.

  Recruiting Mayo Clinic · Scottsdale, Arizona · NCT06470711

• Investigating the effects of DFMO and AMXT 1501 on brain tumor metabolism

  This study is testing how two drugs, DFMO and AMXT 1501, can change the metabolism of brain tumors in patients after surgery.

  Recruiting Early Phase 1 Mayo Clinic · Rochester, Minnesota · NCT05717153

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.